Halberd Corporation (OTC:HALB) President and CEO Bill Hartman and Chief Technology Officer Dr Mitchell Felder tell Proactive that the company has reached a significant milestone after its researchers demonstrated the ability to precisely control the level of PD-1 (programmed cell death–1) in human blood serum in laboratory in-vitro testing. PD-1 is a T-Cell protein that can be used by tumor cells to fool the body’s immune system. Watch video now and read more:
If you are currently looking for healthcare stocks to track then the Halberd Corporation stock may well be the one to look into at this point. The company has been in the news in recent days after its researchers managed to hit a major new milestone with regard to cancer treatment research.
Bill Hartman, the Chief Executive Officer and President of the company spoke to Proactive yesterday and noted that the company’s researchers had displayed that the ability to control the levels of PD-1 in human blood serum to a precise degree. The findings had been made during the course of laboratory in-vitro testing.
The finding was a significant one for Halberd Corporation for a number of reasons and one of the things that investors need to note is the reason why the precise regulation of PD-1 levels is such an important issue. The presence of PD-1 cells in the T-Cell protein can be exploited by the cancer tumor cells to con the immune system of a patient’s body and hence, the tumor may be allowed to grow.
However, if the levels are maintained then it is possible for the immune system to swing into action and then act accordingly to fight the tumor cells. It is going to be interesting to see if the Halberd Corporation stock comes on to the radars of investors over the course of the coming days or not. At this point in time, it may be a good idea to add it to your watch list.